Sinco Pharmaceuticals Holdings Limited 6833.HK Stock
Sinco Pharmaceuticals Holdings Limited Price Chart
Sinco Pharmaceuticals Holdings Limited 6833.HK Financial and Trading Overview
Contents
Sinco Pharmaceuticals Holdings Limited stock price | 0.25 HKD |
Previous Close | 0.33 HKD |
Open | 0.34 HKD |
Bid | 0.32 HKD x 0 |
Ask | 0.33 HKD x 0 |
Day's Range | 0.32 - 0.36 HKD |
52 Week Range | 0.18 - 1.5 HKD |
Volume | 1.02M HKD |
Avg. Volume | 458.07K HKD |
Market Cap | 650.52M HKD |
Beta (5Y Monthly) | 0.555938 |
PE Ratio (TTM) | 8 |
EPS (TTM) | 0.02 HKD |
Forward Dividend & Yield | 0.01 (3.16%) |
Ex-Dividend Date | May 31, 2023 |
1y Target Est | N/A |
6833.HK Valuation Measures
Enterprise Value | 493.46M HKD |
Trailing P/E | 8 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.28638494 |
Price/Book (mrq) | 1.0774411 |
Enterprise Value/Revenue | 0.217 |
Enterprise Value/EBITDA | 4.527 |
Trading Information
Sinco Pharmaceuticals Holdings Limited Stock Price History
Beta (5Y Monthly) | 0.555938 |
52-Week Change | -77.70% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1.5 HKD |
52 Week Low | 0.18 HKD |
50-Day Moving Average | 0.37 HKD |
200-Day Moving Average | 0.33 HKD |
6833.HK Share Statistics
Avg. Volume (3 month) | 458.07K HKD |
Avg. Daily Volume (10-Days) | 295.2K HKD |
Shares Outstanding | 2.03B |
Float | 969.2M |
Short Ratio | N/A |
% Held by Insiders | 52.32% |
% Held by Institutions | 0.12% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0.009 |
Trailing Annual Dividend Yield | 2.72% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 3.05% |
Operating Margin (ttm) | 4.45% |
Gross Margin | 13.46% |
EBITDA Margin | 4.79% |
Management Effectiveness
Return on Assets (ttm) | 4.76% |
Return on Equity (ttm) | 14.19% |
Income Statement
Revenue (ttm) | 2.27B HKD |
Revenue Per Share (ttm) | 1.12 HKD |
Quarterly Revenue Growth (yoy) | -3.00000000000000000000000000000000% |
Gross Profit (ttm) | 305.87M HKD |
EBITDA | 109.01M HKD |
Net Income Avi to Common (ttm) | 69.46M HKD |
Diluted EPS (ttm) | 0.04 |
Quarterly Earnings Growth (yoy) | -87.40% |
Balance Sheet
Total Cash (mrq) | 329.14M HKD |
Total Cash Per Share (mrq) | 0.16 HKD |
Total Debt (mrq) | 192.41M HKD |
Total Debt/Equity (mrq) | 31.87 HKD |
Current Ratio (mrq) | 1.287 |
Book Value Per Share (mrq) | 0.297 |
Cash Flow Statement
Operating Cash Flow (ttm) | 75.08M HKD |
Levered Free Cash Flow (ttm) | 57.81M HKD |
Profile of Sinco Pharmaceuticals Holdings Limited
Country | Hong Kong |
State | N/A |
City | Chengdu |
Address | E5-1805, Global Centre |
ZIP | N/A |
Phone | 86 28 6291 2988 |
Website | https://www.sinco-pharm.com |
Industry | Advertising Agencies |
Sector(s) | Communication Services |
Full Time Employees | 231 |
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers Octapharma, a human albumin solution for use in premature infants; Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections; and Medocef that is used for the treatment of bacterial infections, such as the infections of the lower respiratory tract comprising pneumonia, urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and sepsis. It also provides Esafosfina, which is used for treating hypophosphatemia and chronic diseases, which include alcohol intoxication, malnutrition, and hypophosphatemic respiratory failure; Taurolite, a third generation oral cholic acid drug that is used for the treatment of gallstone diseases; and Tamifil injection for the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis. In addition, the company is involved in the research, development, and sale of pharmaceutical products; provision of warehouse facilities for pharmaceutical products; research and manufacturing of aesthetic medicine; international trade activities; consultation services for medical and biological technology; and medical beauty services. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited is a subsidiary of Risun Investments Limited.
Q&A For Sinco Pharmaceuticals Holdings Limited Stock
What is a current 6833.HK stock price?
Sinco Pharmaceuticals Holdings Limited 6833.HK stock price today per share is 0.25 HKD.
How to purchase Sinco Pharmaceuticals Holdings Limited stock?
You can buy 6833.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Sinco Pharmaceuticals Holdings Limited?
The stock symbol or ticker of Sinco Pharmaceuticals Holdings Limited is 6833.HK.
Which industry does the Sinco Pharmaceuticals Holdings Limited company belong to?
The Sinco Pharmaceuticals Holdings Limited industry is Advertising Agencies.
How many shares does Sinco Pharmaceuticals Holdings Limited have in circulation?
The max supply of Sinco Pharmaceuticals Holdings Limited shares is 2.03B.
What is Sinco Pharmaceuticals Holdings Limited Price to Earnings Ratio (PE Ratio)?
Sinco Pharmaceuticals Holdings Limited PE Ratio is 12.25000100 now.
What was Sinco Pharmaceuticals Holdings Limited earnings per share over the trailing 12 months (TTM)?
Sinco Pharmaceuticals Holdings Limited EPS is 0.02 HKD over the trailing 12 months.
Which sector does the Sinco Pharmaceuticals Holdings Limited company belong to?
The Sinco Pharmaceuticals Holdings Limited sector is Communication Services.